Acurx Pharmaceuticals, Inc.
ACXP· Nasdaq
ACXPAcurx Pharmaceuticals, Inc.
Filed Aug 11, 2025 · 10-Q · 42 days after period end · 0001558370-25-011045
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$2.25M | -$4.12M | -$3.45M | -$2.62M |
| EPS Diluted | -$1.89 | -$5.21 | -$0.28 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acurx Pharmaceuticals, Inc. · CIK 1736243 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 11, 2025 · 42 d after period end
